0.148

2.99% 0.0043

Biorestorative Therapies Inc (BRTX)

Overview News Price History Financials Discussions Forecast Stock Split

Biorestorative Therapies Inc stock is traded at $0.148, with a volume of 692.76K. It is up +2.99% in the last 24 hours and down -29.52% over the past month. BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.

Previous Close:

$0.1437

Open:

$0.1477

24h Volume:

692.76K

Relative Volume:

0.07

Market Cap:

$3.77M

Revenue:

$357.90K

Net Income/Loss:

$-11.06M

P/E Ratio:

-0.1321

EPS:

-1.1201

Net Cash Flow:

$-11.90M

1W Performance:

-25.67%

1M Performance:

-29.52%

6M Performance:

-31.92%

1Y Performance:

-90.92%

1-Day Range:

$0.144

$0.15

1-Week Range:

$0.1425

$0.2099

52-Week Range:

$0.1425

$1.73

Biorestorative Therapies Inc Stock (BRTX) Company Profile

Name

Biorestorative Therapies Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

(631) 760-8100

Address

40 MARCUS DRIVE, MELVILLE

Employee

Twitter

Next Earnings Date

2026-08-25

Latest SEC Filings

BRTX's Discussions on Twitter

Compare BRTX vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BRTX Biorestorative Therapies Inc	0.148	5.62M	357.90K	-11.06M	-11.90M	-1.1201
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Biorestorative Therapies Inc Stock (BRTX) Latest News

Aug 20, 2026

BioRestorative Therapies Halts ExoCR and BioX Shipments - TipRanks

Aug 20, 2026

Aug 19, 2026

BioRestorative Therapies Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView

Aug 19, 2026

Aug 18, 2026

MSN Money - MSN

Aug 18, 2026

BioRestorative Therapies (NASDAQ:BRTX): Why Is Cell-Therapy Development And Manufacturing Readiness in Focus Today? - Kalkine Media

Aug 18, 2026

Aug 17, 2026

BRTX Q2'26 Earnings: EPS estimate is (0.10) USD - TradingView

Aug 17, 2026

Aug 15, 2026

BioRestorative Therapies (BRTX) Holds Near $0.23 as Modest Gains Build on Thin VolumeFundamentals - dars.gov.et

Aug 15, 2026

Form 8K BioRestorative Therapies Inc For: 14 August By Investing.com - Investing.com Nigeria

Aug 15, 2026

Aug 14, 2026

BioRestorative Therapies suspends shipments of ExoCR and BioX products for review - Investing.com

Aug 14, 2026

BioRestorative Therapies Delays Quarterly SEC Filing - TipRanks

Aug 14, 2026

Biorestorative Therapies Suspends All Orders, Shipments Of Exocr, Biox Biocosmeceutical Product Lines Effective Immediately, On Aug 7 - TradingView

Aug 14, 2026

BioRestorative Therapies (BRTX) delays Q2 10-Q amid losses and going-concern risk - Stock Titan

Aug 14, 2026

BioRestorative Therapies, Inc. Suspends All Orders And Shipments Of Biocosmeceutical Product Lines - marketscreener.com

Aug 14, 2026

Aug 11, 2026

BRTX Q2'26 Earnings: revenue estimate is 600.00K USD - TradingView

Aug 11, 2026

Aug 10, 2026

BRTX Q1 2026 Earnings: Narrower-Than-Expected Loss Delivers 41% EPS SurpriseRevenue Guidance Update - vinanet.vn

Aug 10, 2026

Aug 07, 2026